Status: in progress
This study will evaluate the associations between lipid-adjusted serum concentrations of polybrominated diphenyl ethers (PBDEs) and the risk of incident breast cancer in young women, aged 18-44 years. Secondary objectives include: 1) to obtain information on potential dietary exposures (fish consumption, meat, poultry, dairy), environmental (household) and occupational exposures and to evaluate the relative contribution of these sources to lipid-adjusted PBDE serum concentrations; and 2) to collect and store serum and spot urine samples for future biomarker studies of exposure, susceptibility or effect and the risk of breast cancer in premenopausal women.
Breast cancer is the most commonly diagnosed cancer in Canadian women, and it is the leading cause of death in young women. Little is known about the modifiable risk factors for breast cancer and inconsistent findings on the associations between environmental, occupational and dietary risk factors and breast cancer have been reported. These may be explained in part by different etiologies and biological mechanisms for pre- and post- menopausal breast cancers.
Little is known about the risk factors for premenopausal breast cancer, and exposures to environmental pollutants are of concern. A new group of persistent environmental contaminants has emerged: the brominated flame retardants (which include the polybrominated diphenyl ethers: PBDEs). People are exposed both occupationally and environmentally and little is known about their associated human health risks. These chemicals are increasing in the environment, have contaminated the food chain, have been found in high levels in the environment and fatty fish, are endocrine disruptors and toxicological evidence indicates they may increase the risk of certain cancers.
The study is a population-based incident case control study of approximately 700 women. Investigators will collect health/reproductive/lifestyle information including: socio-demographic profile, ethnicity, physical activity, anthropometric, and reproductive characteristics, family history of cancer, sun exposures, recent weight loss and other factors that may act to confound or modify the relationships between PBDE exposures and breast cancer risk. A brief residential and occupational history will be collected and is based on the histories developed by Harris and colleagues, for the Ontario Health Study and the Canadian Partnership for Tomorrow Project (CPT). Additional exposure questions have been created for higher risk occupations including: computer technicians, and workers in electronic warehouses and dismantling plants. Environmental exposure questions were designed to capture major potential sources of exposure to the PBDEs – i.e. exposures through airborne dust particulate, household dust, cleaning, vacuuming, carpeting, and consumer products.
Further, investigators will collect blood and urine samples and test for PBDE concentrations to determine the risk associated with exposures to these compounds. This work is in collaboration with Scientists at Health Canada.
This will be the first study conducted on the association between breast cancer and exposures to PBDEs. This research should help to identify some of the health risks associated with these modifiable exposures, and provide data relevant for the Ontario and Canadian population.
Current status (updated March 2018):
Data collection is now complete. Data analyses are underway to determine the risk of premenopausal breast cancer in relation to serum PBDE concentrations. Additional laboratory analyses of urine samples for organophosphorus flame retardants is underway so that risk associated with these emerging environmental contaminants can be also be assessed.
Shelley Harris (Occupational Cancer Research Centre, Cancer Care Ontario, and University of Toronto)
Paul Villeneuve (Health Canada and University of Toronto)
Beatrice Boucher (Cancer Care Ontario)
Michelle Cotterchio (Cancer Care Ontario)
Linda Kachuri (Occupational Cancer Research Centre)
Len Ritter (University of Guelph)
Julia Knight (University of Toronto)
Cariton Kubwabo (Health Canada)